Video

Dr. Mims on the Emergence of Targeted Therapy in AML

Alice S. Mims, MD, discusses the emergence of targeted therapy in acute myeloid leukemia treatment.

Alice S. Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center—James, discusses the emergence of targeted therapy in acute myeloid leukemia (AML) treatment.

The introduction of targeted therapies, including IDH inhibitors and FLT3 inhibitors, has greatly changed the AML treatment paradigm, particularly the approval of enasidenib (Idhifa), ivosidenib (Tibsovo), and gilteritinib (Xospata), among others, explains Mims.

In March 2017, the FDA approved the IDH2 inhibitor enasidenib for the treatment of patients with IDH2-mutated relapsed/refractory AML. A little over 2 years later, the IDH1 inhibitor ivosidenib was FDA approved in May 2019 for newly diagnosed patients who are ineligible for intensive chemotherapy who are ages 75 or older; it is also approved in the relapsed/refractory setting. The FLT3 inhibitor gilteritinib was FDA approved in November 2018 to treat patients who have FLT3-ITD— or FLT3-TKD–mutated relapsed/refractory AML.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity